Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue
NCT02654444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3
Last updated 2016-01-13
Summary
The purpose of the study is the identification and quantification of protein expression level in breast cancer tissues.
The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying her2 immunohistochemical (IHC) stained samples.
Conditions
Sponsors & Collaborators
-
Applied Spectral Imaging Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 21 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2014-05-31
- Completion
- 2015-01-31
More Related Trials
-
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
NCT06916637 ·Status: RECRUITING
-
Testing a New Imaging Agent to Identify Cancer
NCT04692831 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001496 ·Status: COMPLETED
-
FAST MRI Study in Breast Cancer Survivors
NCT02244593 ·Status: COMPLETED ·Phase: NA
-
99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer
NCT05622240 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics
NCT00656604 ·Status: COMPLETED ·Phase: NA
-
Histolog Comparison to Standard Histology
NCT04857229 ·Status: UNKNOWN
-
HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer
NCT03827317 ·Status: RECRUITING ·Phase: NA
-
HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
NCT02095210 ·Status: TERMINATED ·Phase: PHASE1
-
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.
NCT05203497 ·Status: COMPLETED ·Phase: PHASE1
-
Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
NCT00291304 ·Status: TERMINATED ·Phase: PHASE2
-
Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy
NCT05923268 ·Status: COMPLETED ·Phase: NA
-
Concordance Between Liquid and Tissue Biopsy
NCT04241237 ·Status: UNKNOWN
-
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
NCT02286843 ·Status: COMPLETED ·Phase: NA
-
Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype
NCT06813456 ·Status: RECRUITING
-
68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients
NCT05535621 ·Status: RECRUITING
-
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT04332588 ·Status: RECRUITING ·Phase: PHASE1
-
Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer
NCT04246606 ·Status: COMPLETED
-
Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions
NCT01004666 ·Status: UNKNOWN
-
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
NCT03954431 ·Status: RECRUITING ·Phase: NA
-
Use of Bone Scintigraphy, CT and MRI in Breast Cancer
NCT00682253 ·Status: UNKNOWN
-
Low-field MRI for Breast Cancer Screening
NCT05486520 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
NCT03568448 ·Status: ACTIVE_NOT_RECRUITING
-
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
NCT06830382 ·Status: RECRUITING
-
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
NCT06828588 ·Status: RECRUITING ·Phase: EARLY_PHASE1